Browse studies

Find your next paid study

295 recruiting studies matching your filters

A Multicenter, Phase 1, Open-Label Study of the FGFR Inhibitor Pemigatinib (INCB054828) Administered After Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With Adverse or Intermediate Risk Cytogenetics

This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnos…

Acute Myeloid Leukemia

Estimated

~$10 – $7,500

OHSU Knight Cancer InstituteNCT04659616

Phase 1

HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)

This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing r…

Myeloid MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes

Estimated

~$10 – $6,250

Masonic Cancer Center, University of MinnesotaNCT06594445

Phase 2

A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induct…

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Estimated

~$10 – $7,500

OHSU Knight Cancer InstituteNCT07228273

Phase 1

A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent or Treat Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevent…

Acute Lymphoid LeukemiaAcute Myeloid LeukemiaAcute Undifferentiated Leukemia (AUL)+3 more

Estimated

~$10 – $6,250

University of ArizonaNCT07254793

Phase 2

Phase II Study of TAGraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Previous Exposure to HypOmethylatiNG Agents

A treatment cycle is 28 days. Tagraxofusp will be administered at 9 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 3 consecutive days (or 3 doses over…

Acute Myeloid Leukemia

Estimated

~$10 – $7,500

Joshua ZeidnerNCT05442216

Phase 2

A Randomized, Multicenter, Phase II Study of Maintenance Azacitidine and Venetoclax Versus an Allogeneic Stem Cell Transplant in Older Patients (65 Years and Older) With Acute Myeloid Leukemia Who Achieve an MRD Negative Complete Remission After Induction With Azacitidine and Venetoclax

The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoc…

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06903702

Observational

CD45RA Depleted Peripheral Stem Cell Addback for Patients at Risk for Viral or Fungal Infections Post TCRαβ/CD19 Depleted Hematopoietic Stem Cell Transplant

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD)…

Acute LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndromes+5 more

Estimated

~$10 – $6,250

Children's Hospital of PhiladelphiaNCT03810196

Phase 1

Phase 1 Trial of Autologous CD123-Directed CAR T-Cells (CART123) as Monotherapy or in Combination With Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult su…

Acute Myeloid Leukemia (AML)

Estimated

~$10 – $7,500

Stephan Grupp MD PhDNCT07464951

Phase 1

A Phase I Study to Evaluate the Safety of Ruxolitinib in Combination With Azacitidine Maintenance in Patients Undergoing Reduced Intensity Allogeneic Transplant for Acute Myeloid Leukemia (AML)

This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance t…

Acute Myeloid Leukemia

Estimated

~$10 – $7,500

OHSU Knight Cancer InstituteNCT07548983

Longitudinal Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHM…

Germline MutationMyelodysplastic SyndromesAcute Myeloid Leukemia

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT07019155

Observational

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessme…

OncologyMyeloid Leukemia, AcuteCancer

Estimated

~$10 – $6,250

University of RochesterNCT06697600

An Observational Study to Describe the Performance of Caris Chromoseq as Compared to Conventional Cytogenetics, FISH, and NGS Testing Among Patients Receiving the Caris Chromoseq Assay for Hematologic Malignancies

The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk strati…

Acute Myeloid Leukemia (AML)Myelodysplastic (MDS) / Myeloproliferative (MPN) DiseasesMyelodysplatic Syndromes+1 more

Estimated

~$10 – $1,050

Caris Science, Inc.NCT07680868